Pfizer (Argentina) Performance
| PFE Stock | ARS 7,660 260.00 3.51% |
The company holds a Beta of -0.0764, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Pfizer are expected to decrease at a much lower rate. During the bear market, Pfizer is likely to outperform the market. At this point, Pfizer Inc has a negative expected return of -0.23%. Please make sure to check Pfizer's jensen alpha, treynor ratio, value at risk, as well as the relationship between the total risk alpha and maximum drawdown , to decide if Pfizer Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pfizer Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 2 B |
Pfizer |
Pfizer Relative Risk vs. Return Landscape
If you would invest 897,000 in Pfizer Inc on September 22, 2024 and sell it today you would lose (131,000) from holding Pfizer Inc or give up 14.6% of portfolio value over 90 days. Pfizer Inc is producing return of less than zero assuming 1.8574% volatility of returns over the 90 days investment horizon. Simply put, 16% of all stocks have less volatile historical return distribution than Pfizer, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Pfizer Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pfizer's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pfizer Inc, and traders can use it to determine the average amount a Pfizer's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1256
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PFE |
Estimated Market Risk
| 1.86 actual daily | 16 84% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pfizer is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pfizer by adding Pfizer to a well-diversified portfolio.
Pfizer Fundamentals Growth
Pfizer Stock prices reflect investors' perceptions of the future prospects and financial health of Pfizer, and Pfizer fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pfizer Stock performance.
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 52.46 T | |||
| Shares Outstanding | 2.81 B | |||
| Price To Earning | 469.44 X | |||
| Price To Book | 1.60 X | |||
| Price To Sales | 520.74 X | |||
| Revenue | 100.33 B | |||
| EBITDA | 39.58 B | |||
| Cash And Equivalents | 11.7 B | |||
| Cash Per Share | 2.10 X | |||
| Total Debt | 36.2 B | |||
| Debt To Equity | 78.80 % | |||
| Book Value Per Share | 4.13 X | |||
| Cash Flow From Operations | 32.58 B | |||
| Earnings Per Share | 2,081 X | |||
| Total Asset | 181.48 B | |||
About Pfizer Performance
By analyzing Pfizer's fundamental ratios, stakeholders can gain valuable insights into Pfizer's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pfizer has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pfizer has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. PFIZER INC operates under Drug Manufacturers - Major classification in Argentina and is traded on Buenos-Aires Stock Exchange. It employs 92400 people.Things to note about Pfizer Inc performance evaluation
Checking the ongoing alerts about Pfizer for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pfizer Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pfizer Inc generated a negative expected return over the last 90 days | |
| Pfizer Inc has accumulated 36.2 Billion in debt which can lead to volatile earnings |
- Analyzing Pfizer's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pfizer's stock is overvalued or undervalued compared to its peers.
- Examining Pfizer's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pfizer's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pfizer's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pfizer's stock. These opinions can provide insight into Pfizer's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |